Elanco Animal Health Incorporated
ELAN
Rank in Stocks
#1872
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces,... Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Share Price
$22.70
Last synced: 2026-10-20
Market Cap
$11.34B
Change (1 day)
-3.45%
Change (1 year)
4.97%
Country
US
Trade Elanco Animal Health Incorporated (ELAN)
Category
Healthcare
Revenue for Elanco Animal Health Incorporated (ELAN)
Revenue in Jun 2026 TTM: $5.02B
According to Elanco Animal Health Incorporated latest financial reports the company's current revenue (TTM) is $5.02B. In 2023 the company made a revenue of $4.42B an increase over the revenue in the year 2022 that was $4.41B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Elanco Animal Health Incorporated from 2015 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $5.02B | 13.09% |
| 2024 | $4.44B | 0.50% |
| 2023 | $4.42B | 0.14% |
| 2022 | $4.41B | -7.41% |
| 2021 | $4.76B | 45.54% |
| 2020 | $3.27B | 6.59% |
| 2019 | $3.07B | 0.14% |
| 2018 | $3.07B | 6.15% |
| 2017 | $2.89B | -0.84% |
| 2016 | $2.91B | 0.15% |
| 2015 | $2.91B | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 31.71% |
IN
|
